Outpatient total body irradiation (TBI) prior to bone marrow transplantation has been accomplished in a total of 68 pediatric patients. The TBI regimen was fractionated with a total dose of 12 Gy in eight fractions twice daily. Antiemetic therapy consisted of oral ondansetron three times daily throughout the TBI course. Eight patients experienced mild nausea without vomiting, and four patients experienced mild nausea and vomiting. One patient required intravenous hydration after severe nausea and vomiting. Another patient experienced intractable diarrhea and dehydration which required inpatient management. Outpatient TBI prior to bone marrow transplantation is feasible in pediatric patients.
Total body irradiation (TBI) is a frequently used modality prior to bone marrow transplantation (BMT). It serves three important functions: (1) to allow engraftment of stem cells by creating 'space' in bone marrow; (2) to prevent rejection of transplanted cells via immunosuppression; and (3) to destroy residual malignant clonogenic cells. 1 TBI is frequently employed prior to bone marrow transplantation in hematologic malignancies including acute lymphoblastic leukemia, acute myelogenous leukemia and lymphomas.
Acute toxicities of TBI include nausea, vomiting and diarrhea. Historically, TBI was given as a single fraction. Subsequently, both acute and chronic toxicities have been found to be reduced by fractionated TBI. 2 Compounding the problem of nausea and vomiting associated with TBI is highly emetogenic chemotherapy used in bone marrow conditioning regimens.
Excessive vomiting in patients may result in significant electrolyte abnormalities and dehydration, which potentially may increase the nephrotoxicity of various medications. 3 Additionally, excessive vomiting is psychologically distressing, leading to refusal of further therapy.
In the past, hospitalization has been the standard of care for patients receiving TBI in order to facilitate the management of acute side-effects. However, with the introduction of new and superior antiemetics, outpatient TBI is now being performed. Ondansetron, a 5HT-3 receptor antagonist, has been shown to be superior to conventional antiemetic agents in managing radiation therapy-related emesis. 4 To assess the feasibility of outpatient TBI prior to BMT in pediatric patients, we retrospectively reviewed acute toxicity data of 68 patients treated with outpatient TBI.
Methods and materials
Sixty-eight pediatric patients referred to the Department of Radiation Oncology at Northwestern Memorial Hospital, Chicago, IL, underwent TBI prior to marrow conditioning chemotherapy and BMT between May 1992 and April 1997. Mean age was 6.7 years (range 5 months-20 years). Most patients were treated for acute lymphoblastic leukemia (ALL) (n = 45, 66%). Other common histologies included acute myelogenous leukemia (AML) (n = 9, 13%), chronic myelogenous leukemia (CML) (n = 4, 6%) and non-Hodgkin's lymphoma (NHL) (n = 3, 4%). Patient characteristics are listed in Table 1 . Total body irradiation was administered using 4 MV or 10 MV photons produced by a linear accelerator. Patients were treated in a supine position using lateral fields treated at extended source to skin distances (Ͼ100 cm).
All patients received fractionated TBI which consisted of 1200 cGy in eight fractions over 4 consecutive days. Time between fractions was at least 6 h to allow for repair of sublethal radiation damage. Dose was prescribed to the midplane at a depth corresponding to the average of thickness at the umbilicus and hips.
Patients were premedicated with oral ondansetron (Zofran; Glaxo Wellcome Oncology/HIV, NC, USA) three times daily thoughout the TBI course. Doses of ondansetron prescribed were 0.2 mg/kg per dose up to a maximum dose of 8 mg administered orally. Generally, for patients between 4 and 11 years of age, the dose was 4 mg and patients 12 years of age or older received 8 mg per dose.
Results
Sixty-eight patients (100%) completed the prescribed course of total body irradiation. Mild nausea without vomiting was experienced by eight patients (12%). Mild nausea and vomiting were experienced by four patients (6%). The majority of patients (81%) did not experience significant nausea and vomiting. Hospitalization and intravenous hydration was required in one patient with severe nausea and vomiting. One patient required intravenous hydration after intractable diarrhea. Intravenous hydration was not required for the vast majority of patients (97%).
Discussion
Outpatient fractionated total body irradiation prior to bone marrow transplantation is achievable in pediatric patients. It is preferable to inpatient treatment for several reasons. Firstly, exposure to hospital-acquired pathogens is greatly reduced. Secondly, the child is able to remain in the home environment for as long a period as possible. Finally, outpatient TBI represents a significant cost savings in comparison with inpatient therapy. However, outpatient TBI is predicated on the concept of close and diligent monitoring of the patient at the radiation therapy facility in order to screen for the rare patient requiring inpatient care. All pediatric patients received outpatient TBI during the study period and currently.
The 5-hydroxytryptamine-3 receptor antagonists represent a significant advance in antiemetic therapy which has contributed to the feasibility of outpatient TBI. It is important to remember that older antiemetics, such as highdose metoclopramide, have been associated with severe extrapyramidal effects, especially in children. 5 Priestman et al 6 found a significantly increased efficacy of ondansetron in prevention of vomiting compared with prochlorperazine in patients undergoing fractionated radiation therapy to the upper abdomen (61 vs 35%). Henriksson et al 7 also reported significant efficacy of oral ondansetron in the prevention of radiation-induced emesis with 26 of 33 patients (79%) experiencing no emesis during fractionated radiation therapy to the upper abdomen. In our retrospective review, the low incidence of nausea and/or vomiting (19%) may have been related to the lack of a formal questionnaire administered to patients undergoing TBI.
Adverse effects of ondansetron were not addressed by this study but commonly include headache in approximately 18-24% of patients. 8, 9 In most patients the headache is mild and not disabling. Constipation is also common and the drug has been noted to lead to an increase in gastrointestinal transit time in healthy volunteers.
